Compact Navilas Laser System 577s Receives U.S. FDA Clearance
OD-OS has announced FDA 510(k) clearance and immediate U.S. commercial availability of the Navilas 577s, the most compact all-digital system for navigated focal and peripheral laser treatments. Navilas 577s enables physicians to digitally pre-plan the entire laser therapy on fundus images as well as external diagnostic images and precisely execute this therapy plan under computer guidance. Navilas offers focal treatments without a contact lens and infrared illumination for unsurpassed patient comfort. A large field of view and assisted pattern positioning greatly improve speed in panretinal and focal treatments. David Brown, MD, of Retina Consultants of Houston, was the first U.S. physician to treat patients with the new Navilas 577s before FDA clearance, during his visit to Berlin, Germany. Dr. Brown said, "I am very impressed with the new Navilas 577s PRP. It feels ergonomic and straightforward - the system literally lets me paint the peripheral retina with uniform spots in a very short amount of time. It was very well tolerated by the patients, with only topical anesthesia." More information can be found at https://www.od-os.com/en-US/news/detail/compact-navilasR-laser-system-577s-receives-us-fda-clearance/.
Persavita Receives U.S. Patent for Unique Eye Health Supplement Formula
Persavita Inc. has received a United States patent for its natural eye health product, Saffron 2020, a nutritional supplement that is approved to help maintain general eyesight and to support eye health in AMD and cataracts. The patent recognizes the unique benefits for AMD of the combination of saffron and resveratrol that helps the Saffron 2020 formula be effective. Saffron 2020 includes 20mg of high quality saffron, which has been shown to improve vision in patients with dry AMD by changing the way genes work together to repair and maintain cells in the retina. The supplement also contains resveratrol, lutein and zeaxanthin. More information can be found at http://www.prnewswire.com/news-releases/persavita-receives-us-patent-for-unique-saffron-2020-eye-health-formula-602626215.html.
Enrollment Completed in Trial of Stem Cell Therapy Candidate for RP
California-based regenerative medicine company jCyte has completed enrollment in a phase I/IIa trial to study the safety of its stem cell therapy candidate for retinitis pigmentosa. The trial included 28 patients with advanced RP, eight of whom have completed the one-year study. The company’s investigational therapy, jCell, uses injected retinal progenitor cells, which are intended to rescue dying rods and cones and possibly regenerate new ones. The treatment requires a single intravitreal injection. jCyte co-founder Henry Klassen, MD, PhD, said, “So far, trial participants have had no significant side effects, with good tolerance of the injected cells. We are quite gratified by the results.” More information can be found at http://www.newswise.com/articles/jcyte-completes-enrollment-for-phase-i-iia-safety-trial.
Researchers Investigating Changes in the Vitreous on Structural and Mechanical Levels
Biophysicist Moumita Das from Rochester Institute of Technology is leading a National Science Foundation-funded study to explore properties critical to the function of the vitreous and the eye. Her team is investigating changes in the vitreous gel on structural and mechanical levels that result in vision impairment. Ms. Das' team will use experimental and theoretical methods to investigate the biophysical origin of vitreous-related pathologies. More information can be found at https://www.eurekalert.org/pub_releases/2016-11/riot-teh112316.php.
William J. Link Joins Allegro Ophthalmics’ Board of Directorsa
Allegro Ophthalmics has announced that William J. Link, PhD, has been elected to Allegro’s board of directors. Dr. Link is co-founder and a managing director of Versant Ventures, a global healthcare investment firm where he specializes in early stage investing in medical devices. Prior to Versant, Dr. Link was a general partner at Brentwood Venture Capital. With more than two decades of operations experience in the healthcare industry, Dr. Link has a proven record of building and managing large, successful medical product companies, including Chiron Vision where he was co-founder, chairman and CEO until it was sold to Bausch + Lomb in 1997. In addition, Dr. Link founded and served as President of American Medical Optics, which was sold to Allergan in 1986. More information can be found at http://www.allegroeye.com/press-release/william-j-link-phd-joins-allegro-ophthalmics-board-of-directors/.